EIK1001 / Seven and Eight BioPharma 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
EIK1001 / Eikon Therap
NCT04819373: BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Completed
2
1
US
BDB001
Eikon Therapeutics, Seven and Eight Biopharmaceuticals Inc
Tumor, Solid
04/23
05/23
NCT06246110: A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Recruiting
2
70
US
EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
Eikon Therapeutics
NSCLC
12/26
12/27
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
KEYNOTE-914, NCT03486301: BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Active, not recruiting
1
50
US
BDB001, Pembrolizumab
Eikon Therapeutics, Merck Sharp & Dohme LLC
Tumor, Solid
08/24
08/24
NCT04196530: BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Active, not recruiting
1
40
US
BDB001, Atezolizumab, Tecentriq
Eikon Therapeutics, Seven and Eight Biopharmaceuticals Inc
Tumor, Solid
07/24
07/24

Download Options